Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

December 31, 2001

Primary Completion Date

November 30, 2004

Study Completion Date

November 30, 2004

Conditions
Psoriasis
Interventions
DRUG

Alefacept

intramuscular injection (IM)

Trial Locations (43)

4000

Liège

20010

Washington D.C.

25030

Besançon

28006

Madrid

29279

Brest

30263

Newnan

32204

Jacksonville

33781

Pinellas Park

37044

Tours

37072

Goodlettsville

44791

Bochum

46014

Valencia

48038

Clinton Township

60611

Chicago

63110

St Louis

66160

Kansas City

68131

Omaha

71913

Hot Springs

75475

Paris

78229

San Antonio

78759

Austin

79035

Lake Oswego

80337

Munich

92037

La Jolla

93710

Fresno

97210

Portland

08009

Berlin

02919

Johnston

B-1070

Brussels

B-2650

Edegem

T2S 3B3

Calgary

R3C ON2

Winnipeg

E1C 8X3

Moncton

A1B 4S8

St. John's

N6A 3H7

London

N2J 1C

Waterloo

N8W 5L7

Windsor

G1V 4X7

Sainte-Foy

DK-2400

Copenhagen

06202

Nice

01307

Dresden

1100 DE

Amsterdam

L14 3LB

Liverpool

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Biogen

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY